Yet, I assess that Viking Therapeutics’s main growth vector will likely be imputed to its ability to commercialize and ...

A supportive government, modern infrastructure and easily accessible patient population are helping this Asian nation become a top location for clinical trial research. South Korea, a country in ...

Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot ...

NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US). This is an ASCO Meeting Abstract from the 2023 ASCO Gastrointestinal Cancers Symposium. This abstract ...